Yellow ferrite cores of toroidal inductors wrapped with copper wire on green printed circuit board
Credit: Ladislav Kubeš / iStock / Getty Images Plus

Scientists have developed a system that uses low-frequency electromagnetic fields (EMFs) to control gene expression in living cells, advancing minimally invasive medical technology. EMPOWER (Electromagnetic Programming of Wireless Expression Regulation) uses genetically modified cells triggered by nanoparticles electromagnetically stimulated via a proprietary interface to wirelessly regulate gene expression and release therapeutic proteins like insulin.

The study, published in Nature Biotechnology, provides a promising framework for treating chronic diseases like diabetes using wireless, noninvasive methods. ETH Zurich and University of Basel researchers used mice with type 1 diabetes embedded with a capsule of cells transfected with EMPOWER to prove the system’s efficacy. By exposing the mice to magnetic fields every day, the EMPOWER system was able to return their blood-glucose levels to normal. This study illustrates how scientific innovation can advance us toward a future where medicine is efficacious and seamlessly integrated into our lives.

The science behind EMPOWER

At the heart of EMPOWER is a cutting-edge interface between multiferroic nanoparticles and genetically engineered cells. Coated with a biocompatible chitosan layer, these nanoparticles are designed to respond to a low-frequency magnetic field by generating reactive oxygen species (ROS) in the cell cytoplasm. While often linked to cellular stress, ROS is utilized at safe levels to trigger a genetic switch that activates synthetic promoters that drive the expression of target genes.

ROS generation disrupts the interaction between KEAP1 and NRF2, two proteins from a natural cellular mechanism for sensing oxidative stress. When sensing ROS, KEAP1 essentially releases the NRF2 transcription factor, enabling the gene expression regulator to be translocated into the cell nucleus. There, it complexes with small Maf proteins (sMaf) and binds to antioxidant-response elements (ARE) in the regulatory regions of specific genes. This activation drives the expression of target genes critical for the controlled release of therapeutic proteins.

For the study, the researchers encapsulated human cells engineered with the EMPOWER system in alginate microcapsules, which act as a shield against immune rejection while allowing nutrient exchange. These microcapsules were implanted under the skin of diabetic mice. In response to the magnetic field stimulation, the encapsulated cells were programmed to produce insulin, the hormone critical for regulating blood sugar.

Daily exposure to a weak magnetic field for just three minutes induced insulin production and maintained normal blood-glucose levels in the diabetic mice over four weeks. Notably, the system showed excellent reversibility, enabling precise control over insulin release. When the magnetic field was turned off, insulin production ceased, and blood-glucose levels rose, confirming that the system responds directly to external stimulation.

A key advantage of the EMPOWER system is its biosafety. The researchers carefully optimized the nanoparticle concentration to ensure minimal toxicity and demonstrated that the weak magnetic fields used for stimulation avoided unwanted thermal effects in living tissues. Throughout the four-week study, the encapsulated cells showed no signs of leakage, and the implanted devices did not trigger inflammation or adverse immune responses.

Broader implications for biomedical applications

This novel approach holds potential beyond diabetes. The EMPOWER system’s modular nature means it can be adapted for other diseases, such as chronic pain, cancer, or neurological disorders.

While existing gene-therapy approaches often require invasive procedures or face challenges with signal propagation, EMPOWER utilizes low-power EMFs for a wireless solution. This approach bypasses the need for implanted batteries or external devices that can introduce complications and increase patient discomfort. Moreover, the study builds on a growing interest in leveraging physical stimuli—such as light, sound, or magnetic fields—for precise, spatiotemporal control of cellular functions. Compared to other modalities, magnetic fields have the advantage of penetrating tissues without scattering, making them ideal for noninvasive therapies.

Despite the promise, challenges remain before the EMPOWER system can be translated to clinical use. Scaling the technology for human applications will require further testing to ensure its long-term safety and efficacy. Additionally, researchers must refine the system for higher therapeutic protein yields and broader genetic programmability. The next step, according to the authors, involves extending their findings to other therapeutic applications and exploring strategies for delivering the nanoparticles directly into human tissues. They are also investigating ways to enhance the system’s efficiency and make it more affordable for widespread use.

Also of Interest